Jupiter Neurosciences, Inc. (JUNS)
| Market Cap | 19.89M -46.3% |
| Revenue (ttm) | n/a |
| Net Income | -7.60M |
| EPS | -0.23 |
| Shares Out | 34.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,331 |
| Open | 0.5520 |
| Previous Close | 0.5790 |
| Day's Range | 0.5500 - 0.5779 |
| 52-Week Range | 0.4800 - 3.3300 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 27, 2026 |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. It is also involved in the development of JNS102, which is in Phase II tri... [Read more]
Financial Performance
Financial StatementsNews
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neur...
Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resv...
Jupiter Neurosciences to Participate in NobleCon21
Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Financing designed to support Phase 2 Parkinson's trial and accelerate Nugevia ™ product line growth
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Compan...
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq compliance follows positive upward trend in Company's Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a...
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resv...
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resv...
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline ...
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline ...
Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Tuesday.